BioMarin's Gene Therapy Nears European Market After US Setback [Business News Network (BNN) (Canada)]
bluebird bio, Inc. (BLUE)
Last bluebird bio, inc. earnings: 2/18 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.bluebirdbio.com/investor-overview
Company Research
Source: Business News Network
disorder before the end of the year, raising the drugmaker's hopes it can succeed where rival Bluebird Bio Inc. faltered. The one-time infusion for hemophilia could gain European approval at the end of August after getting a key recommendation in June from a regulatory committee, BioMarin Chief Commerical Officer Jeff Ajer said in an interview. The company will then make a country-by-country push to persuade health systems to pay for it, starting with Germany, with broader agreements likely taking about a year to clinch, he said. BioMarin's Roctavian is the latest gene therapy to approach the market. It aims to treat a form of hemophilia, a rare and lifelong bleeding disorder, with a single dose, potentially bringing huge health benefits and cost savings. But governments and insurers have wrestled with questions over longterm results, safety and how to pay for the revolutionary treatments. Roctavian is the first gene therapy to be recommended for approval in Europe for hemophili
Show less
Read more
Impact Snapshot
Event Time:
BLUE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BLUE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BLUE alerts
High impacting bluebird bio, Inc. news events
Weekly update
A roundup of the hottest topics
BLUE
News
- bluebird bio, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before May 28, 2024 to Discuss Your Rights - BLUEAccesswire
- bluebird bio, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BLUEAccesswire
- Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against bluebird bio, Inc. (BLUE)GlobeNewswire
- bluebird bio, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before May 28, 2024 to Discuss Your Rights - BLUEAccesswire
- bluebird bio, Inc. Class Action: Levi & Korsinsky Reminds bluebird bio Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 28, 2024 - BLUEAccesswire
BLUE
Earnings
- 11/7/23 - Beat
BLUE
Sec Filings
- 5/9/24 - Form 8-K
- 5/3/24 - Form 8-K
- 4/26/24 - Form 8-K
- BLUE's page on the SEC website